AKT1 and Miyoshi myopathy: Furthermore, the clinical importance of Akt was demonstrated by elucidating the therapeutic action of systemic administration of Akt inhibitor LY294002 on multiple myeloma (MM)-mediated osteoclast formation in severe combined immunodeficiency (SCID) mice [28].